Molecular Biology Reports

, Volume 39, Issue 9, pp 9133–9138

Prevalence of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in Chechans, a genetically isolated population in Jordan

  • Rana Dajani
  • Raja Fatahallah
  • Abdelrahman Dajani
  • Mohammad Al-Shboul
  • Yousef Khader
Article

Abstract

Background Coagulation factor II G20210A and coagulation factor V (Leiden) G1691A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism. In view of the heterogeneity in their world distribution and lack of sufficient information about their distribution among Chechans, we addressed the prevalence of these SNPs in the Chechan population in Jordan, a genetically isolated population. Methods and Results factor II G20210A and factor V Leiden SNPs were analysed by polymerase chain reaction and restriction fragment length polymorphism (PCR–RFLP) method and Amplification refractory mutation detection system (ARMS) respectively in 120 random unrelated subjects from the Chechan population in Jordan. Among the subjects studied for factor II G20210A mutation there were three individuals carrying this mutation as heterozygous (one female and two male), giving a prevalence of 2.5 % and an allele frequency of 1.25 %. No homozygous factor II allele was found. Factor V Leiden G1691A mutation was detected as heterozygous in 22 of 120 of individuals (17 female and five male) indicating a prevalence of 18.3 % and allele frequency of 9.2 %. No homozygous allele was found. Conclusion Our results indicated that prevalence of factor II G20210A mutation in the Chechan population is similar to prevalence in Jordan and Caucasian populations (1–6 %) while the prevalence of factor V Leiden was higher in the Chechan population compared to Jordan and Caucasian populations (2–15 %).

Keywords

Genetic polymorphisms Ethnicity Thrombosis 

References

  1. 1.
    Bauduer F, Lacombe D (2005) Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 86(1–2):91–99CrossRefPubMedGoogle Scholar
  2. 2.
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67CrossRefPubMedGoogle Scholar
  3. 3.
    Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85(6):1504–1508PubMedGoogle Scholar
  4. 4.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698–3703PubMedGoogle Scholar
  5. 5.
    Dahlback B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90(3):1004–1008CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G (1999) The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341(11):801–806CrossRefPubMedGoogle Scholar
  7. 7.
    Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM (2000) The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 111(4):1223–1229CrossRefPubMedGoogle Scholar
  8. 8.
    Rosendaal FR (1999) Venous thrombosis: a multicausal disease. Lancet 353(9159):1167–1173CrossRefPubMedGoogle Scholar
  9. 9.
    Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U (1997) A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 89(2):397–402PubMedGoogle Scholar
  10. 10.
    Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C, Horellou MH, Seligsohn U (1998) A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 92(4):1119–1124PubMedGoogle Scholar
  11. 11.
    Rees DC, Chapman NH, Webster MT, Guerreiro JF, Rochette J, Clegg JB (1999) Born to clot: the European burden. Br J Haematol 105(2):564–566CrossRefPubMedGoogle Scholar
  12. 12.
    Nasidze I, Ling EY, Quinque D, Dupanloup I, Cordaux R, Rychkov S, Naumova O, Zhukova O, Sarraf-Zadegan N, Naderi GA, Asgary S, Sardas S, Farhud DD, Sarkisian T, Asadov C, Kerimov A, Stoneking M (2004) Mitochondrial DNA and Y-chromosome variation in the Caucasus. Ann Hum Genet 68(Pt 3):205–221CrossRefPubMedGoogle Scholar
  13. 13.
    Kailani W (2002) Chechens in the Middle East: between original and host cultures. Caspian Studies ProgramGoogle Scholar
  14. 14.
    Poncz M, Solowiejczyk D, Harpel B, Mory Y, Schwartz E, Surrey S (1982) Construction of human gene libraries from small amounts of peripheral blood: analysis of beta-like globin genes. Hemoglobin 6(1):27–36CrossRefPubMedGoogle Scholar
  15. 15.
    Bortolin S, Black M, Modi H, Boszko I, Kobler D, Fieldhouse D, Lopes E, Lacroix JM, Grimwood R, Wells P, Janeczko R, Zastawny R (2004) Analytical validation of the tag-it high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms. Clin Chem 50(11):2028–2036CrossRefPubMedGoogle Scholar
  16. 16.
    Eid SS, Rihani G (2004) Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in 200 healthy Jordanians. Clin Lab Sci 17(4):200–202PubMedGoogle Scholar
  17. 17.
    Angchaisuksiri P, Pingsuthiwong S, Aryuchai K, Busabaratana M, Sura T, Atichartakarn V, Sritara P (2000) Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. Am J Hematol 65(2):119–122CrossRefPubMedGoogle Scholar
  18. 18.
    Almawi WY, Keleshian SH, Borgi L, Fawaz NA, Abboud N, Mtiraoui N, Mahjoub T (2005) Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs. J Thromb Thrombolysis 20(3):163–168CrossRefPubMedGoogle Scholar
  19. 19.
    Abu-Amero KK, Wyngaard CA, Kambouris M, Dzimiri N (2002) Prevalence of the 20210 G->A prothrombin variant and its association with coronary artery disease in a Middle Eastern Arab population. Arch Pathol Lab Med 126(9):1087–1090PubMedGoogle Scholar
  20. 20.
    Akar N, Misirlioglu M, Akar E, Avcu F, Yalcin A, Sozuoz A (1998) Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol 58(3):249CrossRefPubMedGoogle Scholar
  21. 21.
    Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79(4):706–708PubMedGoogle Scholar
  22. 22.
    Nusier MK, Radaideh AM, Ababneh NA, Qaqish BM, Alzoubi R, Khader Y, Mersa JY, Irshaid NM, El-Khateeb M (2007) Prevalence of factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians. Neuroendocrinol Lett 28(5):699–703PubMedGoogle Scholar
  23. 23.
    Lucotte G, Mercier G (2001) Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 27(2):362–367CrossRefPubMedGoogle Scholar
  24. 24.
    Garewal G, Das R, Trehan U (1997) Factor V Leiden: prevalence in the indigenous population and cases of thrombosis in North India. Br J Haematol 97(4):940PubMedGoogle Scholar
  25. 25.
    Rahimi Z, Vaisi-Raygani A, Mozafari H, Kharrazi H, Rezaei M, Nagel RL (2008) Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J Thromb Thrombolysis 25(3):280–283CrossRefPubMedGoogle Scholar
  26. 26.
    Rosen SB, Sturk A (1997) Activated protein C resistance—a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem 35(7):501–516PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Rana Dajani
    • 1
  • Raja Fatahallah
    • 2
  • Abdelrahman Dajani
    • 3
  • Mohammad Al-Shboul
    • 4
  • Yousef Khader
    • 5
  1. 1.Department of Biology and BiotechnologyHashemite UniversityZarqaJordan
  2. 2.National Center for Diabetes, Endocrinology and GeneticsAmmanJordan
  3. 3.Faculty of MedicineHashemite UniversityZarqaJordan
  4. 4.Laboratory of Human Embryology, Institute of Medical BiologyA*STARSingaporeSingapore
  5. 5.Department of Community Medicine, Public Health and Family Medicine, Faculty of MedicineJordan University for Science and TechnologyIrbidJordan

Personalised recommendations